CN103751191A - Combination medicine for treating psoriasis - Google Patents
Combination medicine for treating psoriasis Download PDFInfo
- Publication number
- CN103751191A CN103751191A CN201310741958.1A CN201310741958A CN103751191A CN 103751191 A CN103751191 A CN 103751191A CN 201310741958 A CN201310741958 A CN 201310741958A CN 103751191 A CN103751191 A CN 103751191A
- Authority
- CN
- China
- Prior art keywords
- capsule layer
- capsule
- layer
- medicine
- psoriasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a combination medicine for treating psoriasis, which comprises the following components: 5 mg of methotrexate, 80 mg of silymarin, 15 mg of vitamin B4, and 20 mg of famotidine; the medicine is a four-layer capsule; famotidine is filled between the first capsule layer and the second capsule layer; methotrexate is filled between the second capsule layer and the third capsule layer; silymarin is filled between the third capsule layer and the fourth capsule layer; vitamin B4 is filled in the fourth capsule layer; the thick of the first capsule layer is 1 mm; the thick of the second capsule layer is 1 mm; the thick of the third capsule layer is 3 mm; the thick of the fourth capsule layer is 2 mm. The combination medicine for treating psoriasis not only can play a role of treating psoriasis but also can protect liver and stomach in the treating process; the number of leukocyte is kept in the normal level; due to arrangement of the multi-layer capsules, various medicines are independently separated; the practical drug delivery time is controlled; the maximum pharmaceutical effects of medicines are ensured.
Description
Technical field
The present invention relates to a kind of medicine, particularly one is treated psoriatic composition of medicine.
Background technology
Psoriasis is a kind of common chronic inflammatory disease dermatoses.It belongs to the disease of polygenic inheritance, can be brought out by many factors, as wound, infection, medicine etc. all may bring out this disease in susceptible individual.Typical cutaneous manifestations is the red speckle that boundary clearly has silvery white squama.The lighter can show as the patella ulnaris position speckle of several silver coin sizes, and severe one also can be got involved by whole skin.Its physiological pathology mechanism is mainly the abnormal and immune activation of epidermal hyperplasia differentiation.
The higher methotrexate for the treatment of psoriasis oral medicine curative effect is to be directly proportional to dosage size to most patients' clinical application effect at present.The dosage of pressing textbook and Arzneibucs recommendation is effective to most patients, but is difficult to clinical recovery; Patient is dissatisfied.And escalated dose patient's liver function, digestive tract and blood picture are most, occur extremely.
Summary of the invention
For the defect existing in prior art, the object of the present invention is to provide one to treat psoriatic composition of medicine.
The technical solution adopted in the present invention is:
One is treated psoriatic composition of medicine, comprises following component:
Methotrexate 5mg, silymarin 80mg, adenine phosphate 15mg, famotidine 20mg;
Described medicine is 4 layers of capsule; Fill famotidine between the first capsule layer and the second capsule layer; Fill methotrexate between the second capsule layer and the 3rd capsule layer; Fill silymarin between the 3rd capsule layer and the 4th capsule layer; Fill adenine phosphate in the 4th capsule layer;
Described the first capsule layer thickness is 1mm; Described the second capsule layer thickness is 1mm; Described the 3rd capsule layer thickness is 3mm; Described the 4th capsule layer thickness is 2mm.
Tetrahydrofolic acid is the important coenzyme of purine biosynthesis nucleotide and fudr acid in vivo, methotrexate is as a kind of folic acid reductase inhibitor, mainly suppress dihydrofolate reductase and make dihydrofoilic acid can not be reduced into the tetrahydrofolic acid of physiologically active, thereby the transferance of a carbon-based group in the biosynthetic process of purine nucleotides and pyrimidine nucleotide is obstructed, causes the biosynthesis of DNA to be suppressed.In addition, this product also has pair inhibitory action of thymus nucleoside acid enzyme, but the effect that suppresses RNA and protein synthesis a little less than, this product Main Function is in the S phase of cell cycle, belong to cell cycle specific agents, the cell of G1/S phase is also had to retarding action, a little less than the effect of G1 phase cell.
Silymarin is the plant extract extracting from the seed coat of the medicinal plants of Compositae Herba Silybi mariani seed, is yellow powder or crystalloid powder, bitter in the mouth.Be soluble in acetone, ethyl acetate, ethanol and methanol, be insoluble in chloroform, water insoluble.Main component has the Flavonoid substances such as silibinin, Isosilybin, silidianin and Silychristin.This material has following effect: the liver protecting cell is avoided toxicant infringement, especially ethanol and environmental contaminants (pesticide, heavy metal etc.) invasion infringement liver is had to protective effect; Have powerful anti-oxidation function, can avoid free radical destruction by the liver protecting cell, effect outclass vitamin E; Promote the synthetic of protein, accelerate to manufacture new liver cell, or make liver cell self-healing in damaged condition.Therefore be called as " natural hepatoprotective ".The effects such as silymarin has radioprotective, defying age, prevents and treats arteriosclerosis in addition, delay skin aging.This product is widely used in the production of the products such as medicine, health product, cosmetics, food.The current dosage form of silymarin has oral formulations: silymarin tablet, Yiganling tablet, silybin-phosphatidylcholine compound hard capsule.
Adenine phosphate is the constituent of nucleic acid, participates in the synthetic of hereditary material.Can promote leucocyte hyperplasia, leukocyte number is increased, the leukopenia causing for preventing and treating a variety of causes, the leukopenia causing during especially for tumor chemical therapy, also for acute granulocytopenia.The leukopenia, the acute granulocytopenia that for a variety of causes, cause.
Famotidine is histamine H 2 receptor's antagonist.Gastric acid secretion is had to obvious inhibitory action, and its action intensity is stronger more than 30 times than cimetidine, than the strong 6-10 of ranitidine doubly, clinical in gastric and duodenal ulcers, stress ulcer, acute gastric mucosal bleeding, gastrinoma and anti-fluidity esophagitis etc.
The psoriatic composition of medicine for the treatment of of the present invention; can play the psoriatic effect for the treatment of; again can be in therapeutic process the liver protecting stomach function regulating; keep quantity of leucocyte in normal level simultaneously; the setting of multilamellar capsule; by various medicines independently separately, controlled the time of actual administration, guaranteed that medicine brings into play maximum drug effect.
Accompanying drawing explanation:
Fig. 1 is the structural representation of capsule of the present invention.
The specific embodiment
Embodiment
One is treated psoriatic composition of medicine, comprises following component:
Methotrexate 5mg, silymarin 80mg, adenine phosphate 15mg, famotidine 20mg;
As shown in Figure 1, described medicine is 4 layers of capsule; Fill famotidine between the first capsule layer 1 and the second capsule layer 2; Fill methotrexate between the second capsule layer 2 and the 3rd capsule layer 3; Fill silymarin between the 3rd capsule layer 3 and the 4th capsule layer 4; The interior fill adenine phosphate of the 4th capsule layer 4;
Described the first capsule layer 1 thickness is 1mm; Described the second capsule layer 2 thickness are 1mm; Described the 3rd capsule layer 3 thickness are 3mm; Described the 4th capsule layer 4 thickness are 2mm.
Experimental example:
Below by clinical practice, further illustrate Chinese patent medicine of the present invention to treating psoriatic effect.
One, clinical criteria:
Psoriasis vulgaris diagnosis basis predilection site: scalp, extremity are stretched side, knee joint elbow is symmetrical occurs; Erythra feature: silvery white squama, thin film phenomenon and petechial hemorrhage; Special pathological change, the course of disease is chronic, mostly is the heavy summer in winter light, outbreak repeatedly.
The main feature of psoriasis pustulosa diagnosis is on psoriasis vulgaris basis, to occur in batch aseptic pimple, Relapse rate outbreak.Joint type often occurs together in homeliness type or psoriasis pustulosa.The weight of arthrosis symptom is parallel with skin lesion weight.It is dry that erythrodermic whole skin fills the air flushing, and a large amount of desquamations, have history of psoriasis.
According to psoriatic clinical manifestation and pathological characters, be generally divided into following Four types
1, psoriasis vulgaris: erythra generally occurs in scalp, trunk, extremity and stretches side, on skin, to occur red pimple, and expand and be fused into patch or speckle gradually, there are thicker silvery white phosphorus bits on surface, out-of-shape, what have has map or an island sample outward appearance, some skin lesion are less, more, are Caulis et folium pavettae hongkongensis outward appearance, squama layer one deck comes off, wipe gently scurf off and can see the red film of very thin one deck, strike off red film and can see slight petechia, have person for blood dew, medically make again sieve shape hemorrhage, psoriasis vulgaris Clinical symptoms that Here it is.
2, erythrodermic psoriasis: be more serious, more rare one, this kind of refers to and more than 70% is diffusivity redness at about whole skin, kermesinus wellability skin lesion, there are a large amount of bran skin sample scurfs on surface, sometimes in oxter, thigh root and umbilical part make exfoliation and oozing out because of swelling, oropharynx nose and eye conjunctiva can be congested rubescent, and patient often has heating fear of cold, the symptoms such as headache and general malaise.
3, pustular psoriasis: divide general property and limitation.Generalized pustular psoriasis mostly is acute onset, can be within a few days to several weeks general whole body of pustule, first there is the intensive potential pimple of needle point size, be fused into very soon " pus lake ", often, with high heat, arthralgia and general malaise, routine blood test is chemically examined visible leukocytosis, after abscess is dry, desquamation immediately, after scurf comes off, has again new abscess to occur.Limitation psoriasis pustulosa is common with palm toe psoriasis pustulosa, at the both hands palm and toes portion, there is symmetry erythema, in erythema, occur that foxtail millet grain size arrives pimple: approximately dry voluntarily after 1-2 week, after desquamation, there is again new pustule to occur, repeatedly be continuous, course of disease stubbornness.
4, psoriasis arthropathica: rarely found, any age all can occur can betide big or small joint simultaneously, but common be the little joint of wrist, finger and toes, joint of vertebral column also can occur.The joint of pathological changes has redness, pain, serious articular cavity to have hydrops, juxtra-articular skin turgor limitation of activity, joint stiffness of a specified duration, the destroyed situation in visible joint under x-ray when serious, erythrocyte sedimentation rate is fast, the General Symptomies such as heat that often occur together, but rheumatoid agglutinating factor is negative, arthritis type psoriasis, skin lesion, how with the ostraceous skin lesion of thick picture, also can only have the erythema of psoriasis vulgaris and the skin lesion of silver bits.
Differential Diagnosis
1 seborrheic dermatitis skin lesion only limits to the psoriasis of scalp and should differentiate with seborrheic dermatitis.Seborrheic dermatitis skin lesion is squama erythema in the form of sheets, and the tiny greasy yellow that is of squama, strikes off squama without petechial hemorrhage, skin lesion indefinite border, and hypotrichosis attenuates and comes off, and hair is not pencil.
2 secondary syphilids have unclean sexual intercourse and caries callosa history, and erythra extensively distributes, and the palm sole of the foot has keratinization shape desquamation maculopapule, syphilis seropositivity.
3 chronic simple lichens occur in extremity and stretch side and lumbosacral region, and plumpness psoriasis should be differentiated with primary disease, the latter's acute pruritus, and skin lesion is lichen sample pathological changes, almost without squama.
The scorching psoriasis pustulosas of 4 rheumatoid arthritis knuckles should differentiate with primary disease, and the arthritic symptom of the latter is levied symmetry and increased the weight of, and invades the little joint of near-end more, and the rheumatoid factor positive, without the change of psoriatic lesion and first.
Two. administrated method
According to the length of psoriatic's severe extent, sick time, in adopting, with oral capsule of the present invention, treat psoriasis, its method of administration is: once-a-day, and each one, warm water delivery service; One after each meal.Within one month, be to observe a course for the treatment of and curative effect judgement.
Three. curative effect determinate standard
Because psoriasis is the dermatosis of easily examining refractory, thereby psoriatic clinical treatment observation index and curative effect judgement mark
Standard is divided into: during treatment, treatment finish after and visit long term in three periods.
1. treatment phase clinical observation and curative effect judging standard
(1) clinical observation
1. squama: the propagation of epidermis cell is accelerated and hyperacanthosis, causes cuticular hyperkeratosis, makes epidermis renew the fast 7-8 of rate compared with normal epidermis doubly, every 3 days left and right desquamation one decks.Criterion after medication is: squama reduces gradually or appears as effectively without new skin lesion, otherwise is invalid.
2. substrate: it shows as substrate infiltration, plumpness, shows that the stratum germinativum increment of chrotoplast slows down, and hyperacanthosis fades, and substrate skin lesion, by thick attenuation, illustrate effectively, and substrate infiltrates without changing, and plump without attenuation, it is invalid to illustrate.
3. color: due to the expansion of corium superficial part vascular plexus and blood capillary, its skin lesion has the non-fading red appearance of pressure more.After medication, along with the alleviation of the state of an illness, the color of erythra is also light red by red stain, illustrates effectively, otherwise is invalid.
4. scope: skin lesion many and few, indicate the light and heavy of the state of an illness.After medication, new skin lesion stops appearance, and original erythra starts to dwindle from edge, or therefrom mind-set edge disappears gradually, and the erythra that part is large is divided into some fritters, illustrate effectively, on the contrary invalid.
(2) curative effect judging standard:
1. effective: in above four, there are three to be clearly better, or four improvement that all have in various degree; Or binomial disappearance, another binomial improves.
2. effective: to have binomial to improve or a disappearance.
3. invalid: through one course for the treatment of of clinical application, skin lesion is without improving or increasing the weight of.
2. treatment finishes rear clinical observation and curative effect judging standard
(1) clinical observation:
1. squama: observe and whether have new squama to occur.
2. substrate: whether erythra calms down, the smoothness of skin.
3. color: observe and have or not pigmentation or depigmentation.
4. scope: observe whether have new erythra appearance and the situation that disappears of former skin lesion.
(2) curative effect judging standard:
1. clinical cure: skin lesion all disappears, only leaves pigmentation or de-mistake.
2. effective: skin lesion disappears more than 70%.
3. effective: skin lesion disappears between 30-70%.
4. invalid: skin lesion disappears below 30% or do not controlled on the contrary and increase the weight of.
3. visit clinical observation and curative effect judging standard long term
(1) clinical observation:
1. the time: treatment finishes more than latter 1 year or two to three years, visit recovery from illness and recurrence.
2. case: visit case and cause of recurrence that observation is cured.
(2) curative effect judging standard:
1. recurrence: expand or increase the weight of before the treatment of skin lesion Area Ratio.
2. gently recurrence: recurrence skin lesion is former skin lesion below 50%.
Five. clinical treatment result
Drug regimen of the present invention, through all kinds of psoriatics 184 examples of accepting for medical treatment altogether for 2,007 one 2010 are carried out to orally taken for curing, wherein male's 98 examples, women's 86 examples, the age is 18-52 year; Its clinical treatment result, is calculated as according to above-mentioned canonical statistics: recovery from illness (3 years recidivists not are above observed in drug withdrawal) 64 examples, and cure rate is 34.8%; Effective (1 year recidivist not is above observed in drug withdrawal) 78 examples, obvious effective rate is 42.4%; Effectively (symptom obviously alleviates scurf major part and comes off, and still has the small part silver bits person of not moving back) 35 examples, effective percentage is 19%; Invalid (not alleviator 2 courses for the treatment of takes medicine) 7 examples, inefficiency 3.8%; Total effective rate is 96.2%%, there are no larger toxic and side effects.
With way of example, describe the present invention above, but the invention is not restricted to above-mentioned specific embodiment, all any changes of doing based on the present invention or modification all belong to the scope of protection of present invention.
Claims (1)
1. the psoriatic composition of medicine for the treatment of, is characterized in that comprising following component:
Methotrexate 5mg, silymarin 80mg, adenine phosphate 15mg, famotidine 20mg;
Described medicine is 4 layers of capsule; Fill famotidine between the first capsule layer and the second capsule layer; Fill methotrexate between the second capsule layer and the 3rd capsule layer; Fill silymarin between the 3rd capsule layer and the 4th capsule layer; Fill adenine phosphate in the 4th capsule layer;
Described the first capsule layer thickness is 1mm; Described the second capsule layer thickness is 1mm; Described the 3rd capsule layer thickness is 3mm; Described the 4th capsule layer thickness is 2mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310741958.1A CN103751191A (en) | 2013-12-30 | 2013-12-30 | Combination medicine for treating psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310741958.1A CN103751191A (en) | 2013-12-30 | 2013-12-30 | Combination medicine for treating psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103751191A true CN103751191A (en) | 2014-04-30 |
Family
ID=50518623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310741958.1A Pending CN103751191A (en) | 2013-12-30 | 2013-12-30 | Combination medicine for treating psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103751191A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109219451A (en) * | 2016-06-03 | 2019-01-15 | 埃维克辛公司 | Conjoint therapy comprising how unsaturated ketone and folic acid gametophyte |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130045179A1 (en) * | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
-
2013
- 2013-12-30 CN CN201310741958.1A patent/CN103751191A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130045179A1 (en) * | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109219451A (en) * | 2016-06-03 | 2019-01-15 | 埃维克辛公司 | Conjoint therapy comprising how unsaturated ketone and folic acid gametophyte |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102151291A (en) | Use of antrodia camphorata for treating diseases | |
| CN109172670A (en) | Chinese medicine composition and preparation method thereof with liver kidney Metabolism regulation function | |
| CN100417402C (en) | Liposoluble traditional medicine bougie for treating acute and chronic prostatitis, and manufacturing technique thereof | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN102697771A (en) | New application of alpinetin | |
| CN103751191A (en) | Combination medicine for treating psoriasis | |
| CN103405653B (en) | External preparation for treating gouty arthritis | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN108653680A (en) | A kind of navel paster for treating menorrhalgia of cold-stagnation and blood-stasis type | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN103479968B (en) | Traditional Chinese medicine composition for treating heart-fire flaming acne | |
| CN110876796A (en) | Traditional Chinese medicine composition for treating acute gout attack and preparation method and application thereof | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN108938760A (en) | A kind of application of Chinese medicine composition in preparation treatment medicine for treating arthritis | |
| CN103933277A (en) | Tibetan drug for treating gout disease | |
| CN112773806B (en) | Medical application of pharmaceutical composition containing icariin and madecassic acid | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN112773807B (en) | Medical application of composition composed of icariin and asiatic acid | |
| CN102764325B (en) | Chinese medicinal composition for dispelling rheumatism and relieving pain | |
| CN108057102A (en) | Prevention or pharmaceutical composition, preparation method and the purposes for the treatment of urarthritis | |
| CN106822152A (en) | A kind of pharmaceutical composition and its application | |
| CN109419844B (en) | Tibetan medicine composition for treating osteoarthritis pain | |
| CN101428054A (en) | Uses of rhodiola rosea in preventing and treating insulin resistance, and correlated metabolism diseases | |
| CN104398827A (en) | Medicament for treating bronchial asthma | |
| CN103933278A (en) | Preparation method of Tibetan drug for treating gout disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140430 |